1 / 16

Laboratoire Immunité & Infection INSERM UMR-S 945 IFR 113 Paris, France

Laboratoire Immunité & Infection INSERM UMR-S 945 IFR 113 Paris, France. Towards an innovative therapeutic vaccine against HIVgp41preventing CD4 cells sensitivity to NK killing. P DEBRE. PATHOGENESIS. INFECTION. . CD4 non infected cells. Virus. . CD4 infected cells. NK ?.

haven
Download Presentation

Laboratoire Immunité & Infection INSERM UMR-S 945 IFR 113 Paris, France

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Laboratoire Immunité & Infection INSERM UMR-S 945 IFR 113 Paris, France Towards an innovative therapeutic vaccine against HIVgp41preventing CD4 cells sensitivity to NK killing P DEBRE

  2. PATHOGENESIS INFECTION  CD4 non infected cells Virus  CD4 infected cells NK ? HIV, CD4 & NK cells

  3. 40 30 UT 3S 20 10 CD4 2.7% 17.4% 0 NKp44L HIV-1 gp41 Env Fusion Peptide HR1 HR2 TM 517 532 643 678 558 595 3S motif 1- Background : NKp44L is induced during HIV infection by the 3S/gp41 motif Kill % NKp44L CD4 4+ 3- 8+ 8+ 4+ 3- Control PBMC HIV+ PBMC NKp44L MHC-I 40 NKp44 - + p=0.002 30 % NKp44L NK 20 10 0 0 250 500 1000 750 3S : very conserved motif & specific to HIV-1 CD4 / mm3

  4. Summary 40 44L+ 30 % NK Lysis 20 44L- Autologous NK cells HIV infected cells 10 0 100/1 50/1 25/1 12.5/1 E/T ratio HIV virion NKp44 NKp44L gp41 Epitope 3S (SWSNKS) CD4+NKp44L+ cell CD4+ T cell CD4+ T cell lysis Anti-3S Ab ex vivo In vitro CD4+ T cell depletion ? HIV1-infected individuals

  5. gC1qR is the cell-surface receptor of the 3S motif on CD4+ T cells 3S IgM NA HK C1q 3S C3 3S+ agC1qR NA 0 25 50 75 100 125 150 175 NKp44L expression NKp44L expression (MFI) Listeria monocytogenes Staphylococcus aureus Plasmodium falciparum HCV, rubella virus, HSV and HTNV Deletrious effect of NK cells ? Role of gC1qR ! Fausther-Bovendo et al; PLoS Pathogens 2010

  6. 2- Proof of concept in macaques 2-1 : Macaque model of SHIV infection (Vieillard et al, AIDS 2008) 2-2 : Prophylactic vaccination (Vieillard et al, PNAS 2008) 2-3 : Therapeutic vaccination (Vieillard et al, submitted) Collaboration: Roger Le Grand (CEA, Fontenay-aux-roses; France)

  7. SHIV162P3 « prophylactic » vaccination by the 3S-gp41 peptide 3S 3S 3S 1500 NS NS 3S 3S 108 106 1000 3S anti-3S (U/mL) Viral load 104 3S 500 102 0 1 -400 200 -200 0 0 50 100 150 200 50 2000 ** * 40 1500 % CD4+NKp44L+ 30 CD4 / mm3 1000 20 500 10 0 0 0 50 100 150 200 0 50 100 150 200 Days post-infection KLH-control macaques 3S-immunized macaques

  8. SHIV162P3 50 40 30 CRP (mg/ml) 20 100 ** ** 50 ** ** 10 * 75 40 ** 0 % NK lysis 30 50 * % CD4+AnnexinV+ * 20 25 10 0 0 0 14 21 42 LN UI 14 21 42 LN Days post-infection Days post-infection Effect of 3S vaccination on Apoptosis, NK lysis and inflammation SHIV162P3 80 * 60 ** TNF-(pg/ml) ** 40 20 0 0 113 390 397/7 411/21 0 113 390 397/7 411/21 Days post-immunization Days post-immunization 3S-immunized macaques KLH-control macaques

  9. Conclusions • Immunogenicity in cynomolgus (anti 3S response) • BUT Unchanged viral load • Decreased NKp44L expression on CD4+ T cells • Decreased NK cells cytotoxicity on CD4+ T cells • Decreased CD4+ T cells apoptosis • Preservation of CD4+ T cell counts • Decreased immune activation • Decreased inflammation during the acute phase

  10. « Therapeutic » vaccination by the 3S-gp41 peptide 1000 800 600 Anti-3S (AU/ml) 400 200 0 UI UI 0 0 30 30 10 20 10 20 Weeks post-immunization Weeks post-immunization 15000 10000 Anti-KLH (AU/ml) p=0.0006 5000 40 60 ** ** ** 30 0 40 UI 0 30 10 20 % NKp44L Weeks post-immunization 20 % NKp44L 20 10 Poor responder macaque KLH-control macaques 3S-immunized macaques 0 0 Lymph nodes Spleen Rectum

  11. Effect of 3S vaccination on NK lyis K562 CD4 auto P<0.0001 40 50 40 30 30 20 % specific lysis 10 10 0 0 30 30 20 20 20 10 10 0 0 Weeks post-immunization KLH-control macaques 3S-immunized macaques Poor responder macaque * * * * IgM control % specific lysis Anti-NKp44L 30 W0 W10 W32 20 Weeks post-immunization 10 0

  12. Effect of 3S vaccination on apoptosis 60 40 40 * * * * 20 30 Lymph nodes 0 PB Spleen Rectum 20 %CD4+AnnexinV+ %FAS-induced killing 10 0 Lymph nodes Spleen 3S-vaccinated Controls 50 * * 8.7% 28.4% 40 30 % caspase-3 activity 20 10.2% 24.5% 10 0 Spleen Lymph nodes % Caspase-3 activity KLH-control macaques 3S-immunized macaques

  13. Effect of 3S vaccination on central memory CD4 T cells p=0.0401 800 600 CD4+CD28+CD95+/mm3 UI 0 30 10 20 400 200 0 Weeks post-immunization KLH-control macaques 3S-immunized macaques Poor responder macaque

  14. Conclusions • Immunogenicity in cynomolgus (anti 3S response) • Decrease of NKp44L expression • Decrease of apoptosis in lymphoid tissues • Lower lysis activity of NK cells against autologous CD4+ T cells • Preservation of central memory CD4+ T cells

  15. Perspectives Clinical trial Phase I/IIa Animal Model Therapeutic Vaccine Non-infected Asymptomatic phase AIDS HIV-1 infection Antiretroviral Therapy

  16. Partners IFR 113 CEA Laboratoire d’ Immuno-Virologie Roger Le Grand Nathalie Deudreude-Bosquet Aurélien Corneau Isabelle Mangeot-Méderlé … Unité Immunité & Infection Team-2 Patrice Debré Hugues Fausther Bovendo Caroline Petitdemange Alexis Sennepin Vincent Vieillard Team-1 Brigitte Autran Assia Samri Unité Epidémiologie Clinique Dominique Costagliola Service de Virologie Henri Agut Vincent Calvez Daniel Candotti Isabelle Malet Service des Maladies Infectieuses & Tropicales Christine Katlama Grants ANRS Sanofi-Pasteur Bill & Melinda Gates Foundation Agence Nationale de Recherche (ANR) InnaVirVax ORVACS Institut Pasteur Olivier Schwartz Nathalie Sol-Foulion Felix Rey

More Related